Coronary Vasomotor Response to Intracoronary Acetylcholine Injection, Clinical Features, and Long‐term Prognosis in 873 Consecutive Patients With Coronary Spasm: Analysis of a Single‐Center Study Over 20 Years
Koji Sato(Kumamoto University), Hisao Ogawa(Jikei University School of Medicine), Kunihiko Matsui(Kumamoto University), Keisuke Ohba(Kumamoto University), Seiji Hokimoto(Omuta hospital), Sunao Kojima(Kumamoto University), Seigo Sugiyama(Kumamoto University), Eiji Horio(Kumamoto University), Koichi Kaikita(Kumamoto University), Naoki Nakayama(Kumamoto University), Takamichi Ono(Kumamoto University), Hiromi Yoshimura(Kumamoto University), Shinji Tayama(Saiseikai Kumamoto Hospital), Hiroshige Yamabe(Kumamoto University), Kenichi Tsujita(British Heart Foundation)
Cited by 159
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2015|449